www.sperlaghlab.hu                                                                                                                                                           
                                                                                                                                                                                                                                   
 
MENÜ
  1. Katona, I.  B. Sperlágh, A. Sík, A.Kofalvi, E. S.Vizi, K. Mackie and T. F. Freund (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. The Journal of Neuroscience 19:4544-4558.  1999_Presynaptically_located.pdf
  2.  B. Sperlágh, A.  Kőfalvi, J. Deuchars, L. Atkinson, C. Milligan, N. J. Buckley, and E. S. Vizi (2002) Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. J. Neurochem. 81:1196-1211. 2002_Involvement_of_P2X7_receptors.pdf 
  3. Kőfalvi, R.J. Rodrigues, C. Ledent, K. Mackie, E.S. Vizi, R.A. Cunha and B. Sperlágh (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: A combined immunochemical and pharmacological analysis. J Neurosci.  25: 2874-2884. 2005_Involvement_of_cannabinoid.pdf
  4.  E. Milusheva, M. Baranyi, Á. Kittel, B. Sperlágh and E. S. Vizi (2005)  Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment. Free Radical Biology and and Medicine 39: 133-142.     2005_Increased_sensitivity_of_striatal.pdf
  5.  Wirkner K, Kőfalvi A, Fischer W, Günther A, Heike F, Arndt-Gröger H, Nörenberg W, Madarász E, Vizi ES, Schneider D, Sperlágh B., Illés P (2005) Supersensitivity of P2X7 receptors in cerebrocortical cell cultures after in vitro ischemia.  J Neurochem 95:1421-37. 2005_Supersensitivity_of_P2X7.pdf
  6.  Sperlágh, E. S. Vizi, K. Wirkner and P. Illes (2006) P2X7 receptors in the nervous system. Progr in Neurobiol 78:327-346. 2006_P2X7_receptors_in_the_nervous.pdf
  7.  Heinrich A, Kittel A, Csölle C, Vizi E.S., Sperlágh B. (2008)  Modulation of neurotransmitter release by P2X and P2Y receptors in the rat spinal cord. Neuropharmacology 54(2):375-86. 2008_Modulation_of_neurotransmitter.pdf
  8.  Andó R, Méhész B, Gyires K, Illes P, Sperlágh B. (2010) A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J Pharmacol. 159(5):1106-17. 2010_A_comparative_analysis_of_the_activity_of.pdf
  9.  Hracskó Z, Baranyi M, Csölle C, Gölöncsér F, Madarász E, Kittel A, Sperlágh B. (2011) Lack of neuroprotection in the absence of P2X7 receptors in toxin-induced animal models of Parkinsons disease. Mol Neurodegener. 2011 May 4;6:28. 2011._Lack_of_protection_in_the_absence_of_P2X7_receptors_in_toxin-induced_animal_models_of_Parkinsons_disease.pdf
  10.  Heinrich A, Andó RD, Túri G, Rózsa B, Sperlágh B. (2012) K+ depolarization evokes ATP, adenosine and glutamate release from glia in rat hippocampus: a microelectrode biosensor study. Br J Pharmacol. 167(5):1003-20. 2012_K_depolarization_evokes_ATP_adenosine_and_glutamate.pdf
  11.  Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P. (2012) Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimers, Parkinsons and Huntingtons diseases, and amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 21(9):1267-308. 2012expopinmatyus.pdf
  12.  Richter H, Teixeira FM, Ferreira SG, Kittel Á, Köfalvi A, Sperlágh B. (2012) Presynaptic α₂-adrenoceptors control the inhibitory action of presynaptic CB₁ cannabinoid receptors on prefrontocortical norepinephrine release in the rat. Neuropharmacology. 63(5):784-97. 2012._Presynaptic_a2-adrenoceptors_control_the_inhibitory_action_of_presynaptic_CB1_cannabinoid_receptors_on_prefrontocortical_norepinephrine_release_in_the_rat.pdf
  13.  Timár CI, Lorincz AM, Csépányi-Kömi R, Vályi-Nagy A, Nagy G, Buzás EI, Iványi Z, Kittel A, Powell DW, McLeish KR, Ligeti E. (2013) Antibacterial effect of microvesicles released from human neutrophilic granulocytes. Blood. 121:510-8. 2013_Antibacterial_effect_of_microvesicles.pdf
  14.  Csölle C, Andó RD, Kittel A, Gölöncsér F, Baranyi M, Soproni K, Zelena D, Haller J, Németh T, Mócsai A, Sperlágh B.(2013) The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. Int J Neuropsychopharmacol. 16(1):213-33. 2012_The_absence_of_P2X7_receptor1.pdf
  15.  Csölle, C, Baranyi, M, Zsilla G, Kittel Á, Gölöncsér F, Illes, P, Papp E, Vizi E.S. and Sperlágh B, Neurochemical changes in the mouse hippocampus underlying the antidepressant effect of genetic deletion of P2X7 receptors. Plos ONE 2013 Jun 21;8(6):e66547. 2013_Neurochemical_changes_in_the_mouse_hippocampus.pdf
  16. Ficker, C, Rozmer,K, Kató, E, Andó RD, Schumann, L, Krügel, U, Franke, H, Sperlágh, B, Riedel,T, and Illés, P, Astrocyte-Neuron interaction in the substantia gelationosaof the spinal cord dorsal horn via P2X7 receptor-mediated release of glutamate and reactive oxygen species. GLIA.(2014), 62:1671-86. 2014_Astrocyte-Neuron_Interaction.pdf 
  17. Gölöncsér, F, and Sperlágh, B, Effect of genetic deletion and pharmacological antagonism of P2X7 receptors ina mouse animal model of migraine. The Journal of Headache and Pain 2014, 15:24. 2014_Effect_of_genetic_deletion.pdf

  18. Horváth G, Gölöncsér F, Csölle C, Király K, Andó RD, Baranyi M, Koványi B, Máté Z, Hoffmann K, Algaier I, Baqi Y, Müller CE, Von Kügelgen I, Sperlágh B. Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. NEUROBIOL DIS. (2014) 70:162-78.Central_P2Y12_receptor_blockade_alleviates.pdf

  19. Sperlágh B, Illes P. P2X7 receptor: an emerging target in central nervous system diseases. TRENDS PHARMACOL SCI. (2014) doi: 10.1016/j.tips.2014.08.002P2X7_receptor_an_emerging_target_in_central_nervous_system_diseases.pdf

  20. Paul B. Huleatt,Mui Ling Khoo, Yi Yuan Chua, Tiong Wei Tan, Rou Shen Liew, Balázs Balogh, Ruth deme, Flóra Gölöncsér, Kalman Magyar, David P. Sheela, Han Kiat Ho, Beáta Sperlágh, Péter Mátyus, and Christiana L.L. Chai. Novel Arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's Disease.J Med Chem. 2015 Feb 12;58(3):1400-19.doi: 10.1021/jm501722s.https://ewk.hu/_userfiles_/sperlagh/2015%20Novel%20Arylalkenylpropargylamines%20as%20Neuroprotective.pdf

  21. Beamer E, Gölöncsér F, Horváth G, Bekő K, Otrokocsi L, Koványi B, Sperlágh B. Purinergic mechanisms in neuroinflammation: an update from molecules to behavior. Neuropharmacology. 2015 Sep 16. pii: S0028-3908(15)30111-8.https://ewk.hu/_userfiles_/sperlagh/2015_Purinergic%20mechanisms.pdf

     

  22. Mária Baranyi, Pier Francesca Porceddu, Flóra Gölöncsér, Szabina Kulcsár, Lilla Otrokocsi, Ágnes Kittel, Annalisa Pinna, Lucia Frau, Paul B. Huleatt, Mui-Ling Khoo, Christina L. L. Chai, Petra Dunkel, Peter Mátyus, Micaela Morelli and Beáta Sperlágh, Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease. Molecular Neurodegeneration

    2016, 11:6 (13 January 2016)https://ewk.hu/_userfiles_/sperlagh/2016%20Novel%20heteroarylalkenyl%20propargylamine.pdf

  23. Koványi B.,Csölle C., Calovi S., Hanuska A., Kató E., Köles L., Bhattacharya A., Haller J., Sperlágh B., The role of P2X7receptors in a rodent PCP-induced schizophrenia model. Sci Rep. 2016 Nov 8;6:36680. doi: 10.1038/srep36680.https://ewk.hu/_userfiles_/sperlagh/2016%20The%20role%20of%20P2X7%20receptors.pdf
  24. Bekő K., KOványi B., Gölöncsér F., Horváth G., Dénes Á., Környei Z., Botz B., Helyes Z., Müller CE., Sperlágh B,. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017 Mar 27. doi: 10.1111/jth. 13684https://ewk.hu/_userfiles_/sperlagh/2017%20Contribution%20of%20platelet%20P2Y12.pdf
  25. Helyes Z., Kemény Á., Csekő K., Szőke E., Elekes K., MesterM., Sándor K., Perkecz A., Kereskai L., Mark L., Bona Á., Benkő A., Pintér E., Szolcsányi J., Ledent C., Sperlágh B., Molnár TF. Marijuana smoke induces severe plumonary hyperresponsiveness, inflammation and emphysema in a predictive mouse model not via CB1 receptor activation. AM J Physiol Lung Cell Mol Physiol.2017 May 11:ajplung.0035354.2016. doi:10.1152/ajplung.00354. 2016https://ewk.hu/_userfiles_/sperlagh/2017%20Marijuana%20smoke%20induces.pdf

 

Asztali nézet